Gary N. Schwartz

Gary N. Schwartz

Auto-generated profile, based on publicly available information

Gary N. Schwartz

Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
HRHope Rugo
Hope Rugo
SISeock-Ah Im
Seock-Ah Im
FCFatima Cardoso
Fatima Cardoso
Javier CortesJavier Cortes
Javier Cortes
GCGiuseppe Curigliano
Giuseppe Curigliano
OGon behalf of the SOPHIA Study Group
on behalf of the SOPHIA Study Group
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711 ), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2–positive advanced breast cancer, is reported with updated safety. Overall, 536 patients in the intention-to-treat population were randomly assigned to margetuximab (15 mg/kg intravenously once every 3 weeks; n = 266) plus chemotherapy or trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg; n = 270) plus chemotherapy. Primary end points were progression-free survival, previously reported, and OS. Final OS analysis was triggered by 385 prespecified events. The median OS was 21.6 months (95% CI, 18.89 to 25.07) with margetuximab versus 21.9 months (95% CI, 18.69 to 24.18) with trastuzumab (hazard ratio [HR], 0.95; 95% CI, 0.77 to 1.17; P = .620). Preplanned, exploratory analysis of CD16A genotyping suggested a possible improvement in OS for margetuximab in CD16A-158FF patients versus trastuzumab (median OS, 23.6 v 19.2 months; HR, 0.72; 95% CI, 0.52 to 1.00) and a possible improvement in OS for trastuzumab in CD16A-158VV patients versus margetuximab (median OS, 31.1 v 22.0 months; HR, 1.77; 95% CI, 1.01 to 3.12). Margetuximab safety was comparable with trastuzumab. Final overall OS analysis did not demonstrate margetuximab advantage over trastuzumab. Margetuximab studies in patients with human epidermal growth factor receptor 2–positive breast cancer with different CD16A allelic variants are warranted.

26 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NTNicole A. Traphagen
Nicole A. Traphagen
GSGary N. Schwartz
Gary N. Schwartz
STSteven Tau
Steven Tau
ARAlyssa M. Roberts
Alyssa M. Roberts
AJAmanda Jiang
Amanda Jiang
TMTodd W Miller
Todd W Miller
Purpose: Clinical evidence indicates that treatment with estrogens elicits anticancer effects in ∼30% of patients with advanced endocrine-resistant estrogen receptor α (ER)-positive breast cancer. Despite the proven efficacy of estrogen therapy, its mechanism of action is unclear and this treatment remains underused. Mechanistic understanding may offer strategies to enhance therapeutic efficacy. Experimental Design: We performed genome-wide CRISPR/Cas9 screening and transcriptomic profiling in long-term estrogen-deprived ER+ breast cancer cells to identify pathways required for therapeutic response to the estrogen 17β-estradiol (E2). We validated findings in cell lines, patient-derived xenografts (PDX), and patient samples, and developed a novel combination treatment through testing in cell lines and PDX models. Results: Cells treated with E2 exhibited replication-dependent markers of DNA damage and the DNA damage response prior to apoptosis. Such DNA damage was partially driven by the formation of DNA:RNA hybrids (R-loops). Pharmacologic suppression of the DNA damage response via PARP inhibition with olaparib enhanced E2-induced DNA damage. PARP inhibition synergized with E2 to suppress growth and prevent tumor recurrence in BRCA1/2-mutant and BRCA1/2-wild-type cell line and PDX models. Conclusions: E2-induced ER activity drives DNA damage and growth inhibition in endocrine-resistant breast cancer cells. Inhibition of the DNA damage response using drugs such as PARP inhibitors can enhance therapeutic response to E2. These findings warrant clinical exploration of the combination of E2 with DNA damage response inhibitors in advanced ER+ breast cancer, and suggest that PARP inhibitors may synergize with therapeutics that exacerbate transcriptional stress.

1 January 1994 in Artificial Cells, Blood Substitutes, and Biotechnology
Verified
Journal Article
Closed access
BTB. A. Teicher
B. A. Teicher
GSG. N. Schwartz
G. N. Schwartz
NDN. P. Dupuis
N. P. Dupuis
TKT. Kusomoto
T. Kusomoto
MLM. Liu
M. Liu
DND. Northey
D. Northey
Human solid tumors (prostate carcinomas PC-3 and DU-145, breast carcinoma MX-1, cervical carcinoma ME-180, small cell lung carcinoma SW2, and glioblastoma T98G) were grown as xenografts in nude mice. Using the Eppendorf pO2 histograph microelectrode system, the oxygen profiles of the tumors were determined while the animals breathed air or carbogen (95% O2/5% CO2), and after administration of the perfluorochemical emulsion Oxygent-CA (8 ml/kg) under air breathing and carbogen breathing conditions. Under normal air breathing with or without Oxygent-CA administration the mean oxygen tensions were between 4.9 and 9.3 mmHg and each tumor had severely hypoxic regions where the pO2 was less than 5 mmHg. The severely hypoxic regions comprised 41-71% of the oxygen tension measurements under normal air breathing conditions. Carbogen breathing alone increased the mean oxygen tensions to 10.9-23.9 mmHg. Administration of Oxygent-CA and carbogen breathing increased the mean oxygen tensions over the levels of carbogen breathing alone to varying degrees. The highest mean oxygen tensions were 40.8 mmHg in the T98G glioblastoma and 24.5 mmHg in the ME-180 cervical carcinoma. Investigation of the use of Oxygent-CA/carbogen to increase the oxygenation of clinical tumors is warranted.

10 December 2014 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JBJennifer R. Bean
Jennifer R. Bean
SHSarah R. Hosford
Sarah R. Hosford
LSLynn K. Symonds
Lynn K. Symonds
POPhilip Owens
Philip Owens
LDLloye M. Dillon
Lloye M. Dillon
TMTodd W Miller
Todd W Miller
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway has been implicated in anti-estrogen resistance in breast cancer. We tested the therapeutic potential of the novel PI3K/mTOR dual inhibitor P7170 in a panel of anti-estrogen-sensitive and anti-estrogen-resistant models of ER+ breast cancer. Estrogen receptor-positive (ER+) breast cancer cells were treated ±P7170. Fresh cores from primary ER+/HER2− tumors from two patients were treated ±P7170 ex vivo. Mice bearing breast cancer xenografts were randomized to treatment with vehicle, fulvestrant, P7170, or combinations, and tumor volumes were measured. Tissues and cells were analyzed for markers of pathway activity, cell viability, and apoptosis. In cell lines, P7170 exhibited IC50 values in the range of 0.9–7 nM and induced apoptosis. P7170 potently inhibited mTOR activity (≤25 nM) and inhibited PI3K at higher concentrations (≥200 nM). P7170 completely inhibited MCF-7 tumor growth, significantly inhibited growth of fulvestrant-resistant T47D tumors, and suppressed tumor cell proliferation but did not induce apoptosis. While P7170 inhibits PI3K and mTOR in ER+/HER2− human breast cancer cells and tumors ex vivo, in vivo data indicate that the primary mechanism of P7170 anti-tumor action is inhibition of mTOR and cell proliferation. P7170 is a novel agent worthy of further investigation for the treatment of ER+ breast cancer.

28 February 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
GSGary Schwartz
Gary Schwartz
KSKevin Shee
Kevin Shee
BRBianca Romo
Bianca Romo
JMJonathan Marotti
Jonathan Marotti
AKAlexei Kisselev
Alexei Kisselev
TMTodd W Miller
Todd W Miller
Lessons Learned Fulvestrant is a selective estrogen receptor (ER)‐downregulating antiestrogen that blocks ER transcriptional activity and is approved for ER‐positive breast cancer. Fulvestrant also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. Background Fulvestrant is a selective estrogen receptor (ER)‐downregulating antiestrogen that blocks ER transcriptional activity and is approved for ER‐positive (+) breast cancer. Fulvestrant also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. Methods This is a single‐center phase Ib study with a 3+3 design of fulvestrant and the proteasome inhibitor ixazomib (MLN9708) in patients with advanced ER+ breast cancer that was progressing on fulvestrant. A dose‐escalation design allowed establishment of the ixazomib maximum tolerated dose (MTD). Secondary objectives included progression‐free survival, pharmacokinetics, and tumor molecular analyses. Results Among nine evaluable subjects, treatment was well‐tolerated without dose‐limiting toxicities The MTD of ixazomib was 4 mg in combination with fulvestrant. Plasma concentrations of the active form of ixazomib (MLN2238) in the 4‐mg dose cohort had a median (range) maximal concentration (Cmax) of 155 (122–171) ng/mL, time of maximal concentration (Tmax) of 1 (1–1.5) hour, terminal elimination half‐life of 66.6 (57.3–102.6) hour after initial dose, and area under the curve (AUC) of 5,025 (4,160–5,345) ng*h/mL. One partial response was observed, and median progression‐free survival was 51 days (range, 47–137). Conclusion This drug combination has a favorable safety profile and antitumor activity in patients with fulvestrant‐resistant advanced ER+ breast cancer that justifies future testing.

1 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GSGary N. Schwartz
Gary N. Schwartz
PKPeter A. Kaufman
Peter A. Kaufman
KGKarthik Giridhar
Karthik Giridhar
JMJonathan D. Marotti
Jonathan D. Marotti
MCMary D. Chamberlin
Mary D. Chamberlin
TMTodd W Miller
Todd W Miller
Purpose: Strategies to implement estrogen therapy for advanced estrogen receptor–positive (ER+) breast cancer are underdeveloped. Preclinical data suggest that cycling treatment with 17β-estradiol followed by estrogen deprivation can control tumor growth long-term. Patients and Methods: Postmenopausal women with advanced ER+/HER2− breast cancer with recurrence or progression on ≥ 1 antiestrogen or aromatase inhibitor (AI)-based therapy were eligible. Patients received 17β-estradiol (2 mg orally, three times a day) for 8 weeks followed by AI (physician's choice) for 16 weeks, alternating treatments on an 8-week/16-week schedule until disease progression. Patients then optionally received continuous single-agent treatment until a second instance of disease progression. Endpoints included 24-week clinical benefit and objective response per RECIST, and tumor genetic alterations. Results: Of 19 evaluable patients, clinical benefit rate was 42.1% [95% confidence interval (CI), 23.1%–63.9%] and objective response rate (ORR) was 15.8% (95% CI, 5.7%–37.9%). One patient experienced a grade 3 adverse event related to 17β-estradiol. Among patients who received continuous single-agent treatment until a second instance of disease progression, clinical benefit was observed in 5 of 12 (41.7%) cases. Tumor ER (ESR1) mutations were found by whole-exome profiling in 4 of 7 (57.1%) versus 2 of 9 (22.2%) patients who did versus did not experience clinical benefit from alternating 17β-estradiol/AI therapy. The only two patients to experience objective responses to initial 17β-estradiol had tumor ESR1 mutations. Conclusions: Alternating 17β-estradiol/AI therapy may be a promising treatment for endocrine-refractory ER+ breast cancer, including following progression on CDK4/6 inhibitors or everolimus. Further study is warranted to determine whether the antitumor activity of 17β-estradiol differs according to ESR1 mutation status.